Autopsy report · NCT00771316

Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)

“feasibility and low enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 6 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Merck Sharp & Dohme LLC

Sponsor type

Industry

Conditions

Urinary Tract Infections

Interventions

MK0826 (ertapenem); Comparator: meropenem

Participants

6

Trials that died the same way

• Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations
  “Poor enrollment, lack of feasibility” (88% match in meaning)
• Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.
  “Low enrollment” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.